Additionally, Reckitt Benckiser allegedly fraudulent claimed to the Food and Drug Administration (FDA) that it stopped manufacturing and selling Suboxone Sublingual Tablet “due to safety concerns.”
Furthermore, the pharmaceutical distributor allegedly took steps to delay the entry of generic competition of for various forms of Suboxone. Its actions allowed it to improperly control the pricing of the drug in the market and to federal healthcare programs.
Reckitt Benckiser to pay $700 million settlement
According to Pennsylvania Attorney General Josh Shapiro, Reckitt Benckiser agreed to pay $700 million to the plaintiff states to settle the accusations against it.
As part of the settlement, $400 million will go to the Medicaid programs. Pennsylvania will receive more than $53 million and the remaining amount will go the other plaintiff states.
In a statement, AG Shapiro said, “Suboxone is critical for helping individuals recovering from substance abuse disorder… But this company improperly marketed it by not revealing its risks and promoting it to physicians with unsafe prescribing practices.”
